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Background: Curcumin, the active ingredient from turmeric rhizomes, has been shown to 
have a wide range of pharmacological properties including antioxidant and anti-inflammatory 
effects. Curcumin has been reviewed for its multiple molecular action on inhibiting tumor 
angiogenesis via its mechanisms of cyclooxygenase (COX)-2, and vascular endothelial growth 
factor (VEGF) inhibition. In this present study, we aimed to assess the effects of curcumin on 
preventing diabetes-induced vascular dysfunction in association with COX-2, nuclear factor-κB 
(NF-κB) expression, and prostanoid production.
Methods: Twelve-week-old male Wistar rats were separated into five groups: 1) diabetes with 
0.9% normal saline (DM-NSS; n = 10), 2) diabetes treated with curcumin 30 mg/kg (n = 10), 
3) diabetes treated with curcumin 300 mg/kg (n = 10), 4) the control with 0.9% normal saline 
(n = 10), and 5) the control treated with 300 mg/kg (n = 10). Daily oral feeding of curcumin was 
started at 6 weeks after the streptozotocin   injection. Levels of 6-keto prostaglandin (PG) F1α and 
thromboxane (TX) B2 were determined from mesenteric perfusates using enzyme immunoassay 
kits. Protein kinase C (PKC)-βII and COX-2 with NF-κB levels were analyzed in the mesenteric 
arteries by immunofluorescent staining and immunohistochemistry, respectively.
Results: The ratio of 6-keto-PGF1α and TXB2 was significantly decreased in DM-NSS compared 
with the control (P , 0.05). Double-immunofluorescent staining with specific antibodies for 
PKC-βII and α-smooth muscle actins showed that the diabetic mesenteric arteries contained 
increased of PKC-βII within the vascular wall. Also, COX-2 expression and activated NF-κB 
in the small mesenteric artery of diabetes mellitus rats were markedly increased when com-
pared with the control. Interestingly, curcumin could inhibit the upregulation of all of these 
biomarkers.
Conclusion: These findings show that curcumin can attenuate diabetes-induced vascular 
  dysfunction in association with its potential for COX-2 and NF-κB suppression, PKC   inhibition, 
and improving the ratio of prostanoid products PGI2/TXA2.
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Introduction
Diabetes mellitus (DM) is a common metabolic disease with a high and growing preva-
lence affecting 4% of the population worldwide: 171 million people in the year 2000 
and an expected 366 million in 2030.1 Diabetic vascular diseases   represent a major 
cause of mortality and morbidity in diabetic patients. Both micro- and   macrovascular 
complications are the burden of the disease, not only in terms of   individual health 
and wellbeing, but also in terms of the impact on the economic status of a patient’s 
family and their country.2 It is suggested that hyperglycemia induces an intracellular 
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cause long-term changes in the   structure and functions of 
macromolecules, including   protein,   lipids, and DNA. With 
this rationale, the dysfunction of the endothelial cells has 
been documented as a common finding in diabetic patients 
with its underlining causes of oxidative stress. The   potential 
  contribution of increased ROS to the   development of endothe-
lial dysfunction in diabetes has received   considerable interest, 
since it interferes with the production of nitric oxide (NO), 
a key factor in multiple processes of vascular   functional 
homeostasis. It has been pointed out that one of the major 
pathways that increases ROS production in endothelial 
cells is the diacylglycerol (DAG)–protein-kinase C (PKC) 
pathway. Moreover, high-glucose activated PKC upregula-
tion has been reported for its significant role in inducing 
diabetic endothelial dysfunction.3–6 It has been demonstrated 
that oxidative stress will be produced more and more via 
this PKC upregulation, which leads to the activations of 
nuclear factor-κB (NF-κB) and cyclo-oxygenase (COX)-2 
expressions.7–11 Previous studies have shown that in vitro 
incubation of rabbit arteries with a high glucose concentra-
tion increases vasoconstrictor prostanoids. These effects were 
prevented by both COX inhibitors and prostaglandin (PG)H2/
thromboxane (TX)A2 receptor antagonist, thereby   restoring 
endothelium-  dependent relaxation.8 Recent biochemical 
studies have   proposed a possible role for enhanced COX-2 
expression in high glucose-induced alterations in vasocon-
strictor prostanoid production in cultured endothelial cells.9 
Also, it has been demonstrated that upregulation of COX 
isoforms is associated with a significant elevation of vascular 
prostaglandin synthesis.10 However, there have been only a 
limited number of studies investigating the consequences of 
alterations in   microvascular prostanoid synthesis.11
Curcumin, which has been shown to have a wide range 
of pharmacological properties including antioxidant and 
anti-inflammatory effects, has been reviewed for its multiple 
molecular targets on inhibiting PKC, COX-2, and NF-κB 
expressions.12–14 The antioxidant effect of curcumin has been 
found to be at least 10 times greater than that of vitamin 
E. It has been demonstrated that the antioxidant activity of 
curcumin could be mediated through antioxidant enzymatic 
systems including superoxide dismutase (SOD), catalase, 
and glutathione peroxidase.15,16
Even though the beneficial effect of curcumin treatment on 
hypoglycemia in streptozotocin (STZ)-induced diabetes rats 
has been reported,17 its molecular mechanisms have not been 
clarified yet. The mechanism by which curcumin improves this 
situation is probably due to its   hypocholesterolemic influence, 
antioxidant nature, and increase in plasma insulin levels.18–20
The anti-inflammatory effects of curcumin have been shown 
to mediate through the suppression of both COX-2 and lipoxy-
genase proteins as well as the downregulation of NF-κB. The 
anti-inflammatory pathways of curcumin have been discovered 
mostly from the tumor cell study, however, the effects of cur-
cumin on a diabetic animal model remain unknown.20–22
Therefore, in the present study, we aimed to assess the 
effects of plant-derived antioxidant, curcumin, on diabetes-
induced endothelial dysfunction in association with its 
mechanism on NF-κB, COX-2, and prostanoid ratio.
Method
Twelve-week-old male Wistar rats were housed in a tem-
perature- and light-controlled environment, and were fed 
standard feed and drank tap water ad libitum. The present 
study was conducted in accordance with the guidelines for 
animal experimentation established by the National Research 
Council of Thailand and approved by the Institutional Animal 
Care and Use Committee of Chulalongkorn University.
induction of experimental diabetes
The rats were randomly divided into nondiabetic and diabetic 
groups. Diabetic rats were induced by a single intravenous 
injection of STZ (55 mg/kg) (Sigma-Aldrich, St. Louis, MO). 
STZ was freshly prepared by dissolving in citrate buffer pH 
4.5 (Sigma-Aldrich) and immediately injected into the tail 
vein after 8 hours of fasting. The control rats received instead 
a citrate buffer of the same volume. STZ-induced diabetic 
rats were included and retained for the experiments if their 
blood glucose was greater than 200 mg/dL. Blood glucose 
was measured using a glucometer (ACCU-CHEK, ADVAN-
TAGE; Roche Diagnostics, Mannheim, Germany). Animals 
were separated into five groups: 1) diabetes treated with 0.9% 
normal saline group (DM-NSS; n = 10), 2)   diabetes treated 
with curcumin (Cayman Chemical, Ann Arbor, MI) 30 mg/kg 
dissolved in corn oil (DM-CUR30; n = 10), 3) diabetes treated 
with curcumin 300 mg/kg (DM-CUR300; n = 10), 4) control 
treated with 0.9% normal saline group (CON-NSS; n = 10), 
and 5) control treated with 300 mg/kg bodyweight (CON-
CUR300; n = 10). It is noted that the daily oral feeding of 
  curcumin was started at 6 weeks after the STZ injection since it 
was shown in our previous study that endothelial   dysfunction 
in STZ-rats occurred 6 weeks after STZ injection.23 The feed-
ing of curcumin was continued for 8 weeks.
Measurement of metabolic parameters
At the end of each experiment, a blood sample from each rat 
was collected for further plasma glucose and glycosylated Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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hemoglobin (HbA1c) determination, using the enzymatic 
method and the turbidimetric immunoinhibition method, 
respectively (Bangkok RIA Laboratory Co. Ltd, Bangkok, 
Thailand).
Determination of prostanoid levels
PGI2 is rapidly hydrolyzed nonenzymatically from 6-keto-
PGF1α. Therefore, in most studies, 6-keto-PGF1α is widely 
used as an indicator for determining PGI2 production. TXB2, 
which is the hydrolysis product of TXA2, is commonly used 
as an indicator of TXA2 production as well.
Under pentobarbital sodium anesthesia, the abdominal 
cavity was opened via the midline position. The mesentery 
was exteriorized. The ileocecal portion of the mesentery was 
carefully spread on a plexiglass chamber and continuously 
perfused by 1 mL/min Kreb-Ringer buffer solution (37°C, 
pH 7.4 composition in mmol/L; 135.7 NaCl, 4.7 KCl, 2.52 
CaCl2, 1.18 KH2PO4, 1.64 MgSO4.7H2O, and 7.14 NaHCO3) 
for 15-minute equilibration. After 15 minutes, 1 mL of the 
mesenteric perfusate was collected immediately for the mea-
surements of existing 6-keto-PGF1α and TXB2 (basal level). 
The levels of 6-keto-PGF1α and TXB2 were determined by 
using enzyme immunoassay kits. According to the manufac-
turer’s protocols (Cayman Chemical), the quantitative levels 
of 6-keto-PGF1α and TXB2 could be assessed by the standard 
calibration curves of both substances.
Immunofluorescent staining for PKC-βii
Under pentobarbital sodium anesthesia, the rat mesentery 
was exposed. A single unbranched small mesenteric artery 
with a diameter of approximately 100 µm was selected 
for study. The selected microvessel was then dissected 
and cleared of connective tissue and briefly rinsed in ice-
cold phosphate-buffered saline (PBS). After collection, 
the mesenteric   arteries were then immediately fixed in 
4% paraformaldehyde for 24 hours and were embedded 
in paraffin. These specimens were then deparaffinized in 
xylene, rehydrated in graded ethanol and distilled water, 
and the antigen unmasked with sodium citrate (10 mmol/L, 
pH 6.0) (Dako, Glostrup,   Denmark), followed by a micro-
wave heat source on high power for 3 minutes and then 
with low power for 10   minutes. After the PBS wash, the 
nonspecific   background was blocked with 3% normal 
horse serum at room   temperature for 20 minutes. Incuba-
tion with anti-PKC-βII (1:100 dilutions) (SC-210; Santa 
Cruz Biotechnology, Santa Cruz, CA) was performed at 
room temperature for 60 minutes. Anti-α-smooth muscle 
actin (1:200 dilutions) (Dako) was also used to colocalize 
microvascular smooth muscle. Sections were then washed 
in PBS and incubated with the secondary antibody swine 
anti-rabbit IgG-TRITC (1:50 dilution) (R0156; Dako) for 
PKC-βII and rabbit anti-mouse IgG-FITC (1:50   dilution) 
(R0261; Dako) for smooth muscle actin at room temperature 
for 30   minutes. The arteries received two 3-minute washes 
in PBS and were covered with mounting medium   containing 
DAPI (4,6-diamidino-2-phenylindole) (Vector   Laboratories, 
Burlingame, CA) for fluorescent counterstaining of nuclei. 
Labeling of the arteries with secondary antibody alone was 
used as negative controls. Images were obtained using laser 
scanning   confocal microscopy (E800; Nikon, Tokyo, Japan) 
to establish the localization of PKC-βII and α-smooth 
muscle actin in the small mesenteric arteries.
immunohistochemistry for cOX-2
After the collection, the mesenteric arteries were fixed by 
the same protocol. Paraffin-embedded sections of the mes-
enteric arteries were sequentially exposed to the solutions 
as described previously. COX-2 was immunohistochemi-
cally detected by incubation with rabbit anti-COX-2 (1:500 
dilutions) (RP111; Diagnostic Biosystems, Pleasanton, CA) 
followed by the appropriate secondary antibody, anti-rabbit 
IgG horseradish peroxidase.
immunohistochemistry for nF-κB
Activated NF-κB was detected by incubation with anti-
NF-κB p65 rabbit polyclonal antibody (1:150 dilution) 
(SC-109; Santa Cruz Biotechnology), which was recognized 
as an epitope accessible only when NF-κB is bound to 
DNA. This was followed by incubation with a   horseradish 
  peroxidase-conjugated secondary antibody. The data were 
expressed as a positive signal in the vasculature. The 
stained sections were examined under a microscopy system 
(Optiphot 2; Nikon) equipped with Nikon Digital Sight 
DS-Fi1, DS-L2, and 20× objective lens (CF Plan Fluor; 
Nikon).
Quantitative analysis for the amount of COX-2 and NF-κB 
p65 was measured using Global Lab Image/2 software (Data 
Translation, Marlborough, MA). Using the histogram tool 
of the software, both the lowest and highest intensity values 
in the brown immunoreactive area were determined, and then 
the total number of pixels which had the intensity within 
those threshold values was obtained for small regions of 
interest (ROI) (45 × 45 pixels). Means ± standard error of 
mean (SEM) of the total number of pixels of immunoreac-
tions of COX-2 or NF-κB p65 were calculated by averaging 
the small ROI of each video frame.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
424
Rungseesantivanon et al
Mean number of pixels within the brown immunoreac-
tions = x1 + x2 + x3 + … + xn,
 n
where, xi is the total number of brown-precipitate pixels in 
each ROI, and n is the total number of ROI in each video 
frame.
Statistical analysis
All data were expressed as mean ± SEM. For comparison 
among groups of animals, one-way analysis of variance 
(ANOVA) was used. Also Tukey’s post-hoc test was used 
when comparing the difference of the means between the 
diabetic rats and the controls, and between the diabetic-
untreated and diabetic-treated animals. The statistical 
probabilities, P , 0.001, P , 0.01, and P , 0.05, were 
considered statistically significant. The data were analyzed 
with the SPSS program for Windows (version 16.0; SPSS 
Inc., Chicago, IL).
Results
In Table 1, bodyweight, mean arterial blood pressure 
(mABP), plasma glucose, and HbA1c values are shown for 
each group. The blood glucose and percentage of HbA1c 
of all diabetic groups (DM-NSS, DM-CUR30, and DM-
CUR300) were significantly higher than those of the control 
(P , 0.01). Interestingly, among DM-NSS, DM-CUR30, and 
DM-CUR300, there was a significant difference in percentage 
of HbA1c (P , 0.05).
Only the DM-NSS group had a significantly increased 
mABP when compared with the CON-NSS group (P , 0.01). 
Conversely, the levels of mABP of DM-CUR30 and DM-
CUR300 were significantly lower than those of age-matched 
untreated diabetic rats (P , 0.05).
Supplementation of curcumin 30 and 300 mg/kg per day 
could lower blood glucose in the diabetic group down to 
18.73% and 30.26%, respectively. This antidiabetic action of 
curcumin is confirmed by previous reports, which show that 
curcumin can mediate its hypoglycemic effect through the 
stimulation of the pancreas to produce and secrete insulin.24–27 
Treatment of streptozotocin in our diabetes model causing beta 
cell destruction leads to hyperglycemia with hypoinsulinemia. 
However, limited B-cells regeneration may occur, allowing 
cellular responses to curcumin activation.  However, the cur-
cumin supplementation could not reduce blood glucose back 
to its normal state. The blood glucose and HbA1c of both DM-
CUR30 and DM-CUR300 still significantly increased when 
compared with CON-NSS. In other words, the antidiabetic 
effect of curcumin is not great enough to be used alone.
In Figure 1, immunofluorescent staining of small mesenteric 
arteries displays a strong signal for PKC-βII in the diabetic rats 
(Figure 1B). Double-immunofluorescent staining with specific 
antibodies for PKC-βII and α-smooth muscle actin shows that 
the diabetic mesenteric arteries contained   PKC-βII within the 
vascular smooth muscle cells (Figure 1C). Interestingly, supple-
mentation with curcumin (300 mg/kg) could reduce PKC-II 
expression in DM-CUR 300, with results looking similar to 
the control staining results. It is noted that the negative control 
displays a minimal detectable fluorescence when the secondary 
antibodies were used alone. These results suggest that mesen-
teric vessels in the DM-NSS have higher levels of PKC-βII 
both in the endothelium and the smooth muscle cells.
Figure 2A and 2B demonstrate that COX-2 expression in the 
small mesenteric artery of the DM rats was   markedly increased 
when compared with the control. Curcumin supplementation 
reduced COX-2 expression in the mesenteric microvessels 
significantly when using low and high doses of curcumin 
(DM-CUR30, P , 0.05; DM-CUR300, P , 0.01); although 
these reduced COX-2 expressions do not seem to completely 
eliminate the COX-2 expression in diabetic arteries.
Figure 3A and 3B demonstrate that NF-κB p65 was 
expressed more in the diabetic small mesenteric arteries 
when compared with the control. DM-CUR300 seemed to 
attenuate this diabetes-induced NF-κB p65 upregulation 
significantly (P , 0.05).
Table 1 Bodyweight and mean arterial blood pressure, blood glucose, and percentage hbA1c
Group BW (g) mABP (mmHg) BG (mg/dL) HbA1c (%)
cOn-nSS 398.7 ± 12.3 103.1 ± 3.5   101.8 ± 4.89   3.68 ± 0.17
cOn-cUR300 403.8 ± 17.0  106.1 ± 3.9    106.8 ± 0.92    4.08 ± 0.41 
DM-nSS 285.3 ± 8.8a 151.6 ± 9.6a   459.0 ± 24.40a 10.73 ± 0.32a
DM-cUR30 292.7 ± 17.8a 128.3 ± 3.6c   360.8 ± 35.82a   8.20 ± 0.88a,c
DM-cUR300 325.7 ± 13.0b 122.2 ± 8.6c 310.00 ± 32.73a,c   7.90 ± 0.97a,c
Notes: aP , 0.01 significant difference compared with control; bP , 0.05 significant difference compared with control; cSignificant difference compared with diabetic rat   
(P , 0.05). Values are means ± SeM (n = 10 for each group).
Abbreviations: Bg, blood glucose; BW, bodyweight; cOn-nSS, control with 0.9% normal saline; cOn-cUR300, control treated with 300 mg/kg; DM-cUR30, diabetes-
treated with curcumin 30 mg/kg; DM-cUR300, diabetes-treated with curcumin 300 mg/kg; DM-nSS, diabetes with 0.9% normal saline; hbA1c, glycosylated hemoglobin; 
mABP, mean arterial blood pressure; SeM, standard error of the mean.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
425
curcumin improves prostanoid ratio in diabetic mesenteric arteries
Table 2 indicates that 6-keto-PGF1α release was significantly 
decreased in the DM group (407.6 ± 37 pg/mL) when com-
pared with the control (536.9 ± 53.3 pg/mL) (P , 0.05). 
There was a significantly increased TXB2 production 
in the DM group (58.4 ± 5.8 pg/mL) when compared with 
their respective controls (29.4 ± 4.3 pg/mL) (P , 0.05). 
In   addition, there was a significantly decreased 6-keto-
PGF1α/TXB2 ratio in the DM group (7.0) when compared 
with their respective controls (18.4) (P , 0.05). It is to be 
noted that in the prostanoids ratio study, only the high-dose 
supplementation of curcumin (DM-CUR300) was conducted. 
This high dose could be a more effective dose of curcumin 
supplementation to reduce the diabetes-induced vascular 
NF-κB p65 and COX-2 upregulation.
Discussion
In the present study, we have shown that the effects of 
curcumin supplementation on attenuating diabetes-induced 
endothelial dysfunction are closely associated with its anti-
oxidant and anti-inflammatory properties. Two doses of 
curcumin were used in this study. The rationale of these low 
and high doses was based on the literature reviews that each 
antioxidant and anti-inflammatory action was indicated by 
different optimal doses.20 A high dose of curcumin supple-
mentation seems to prevent the dysregulation for the multiple 
signaling pathways induced by diabetes. As such, the idea that 
curcumin may help prevent diabetic vascular complications 
was confirmed by the present finding that supplementation 
with a high dose of curcumin, 300 mg/kg per day, appears to 
improve the diabetic endothelial functions which was shown 
by the decrease in mABP and the suppression of COX-2 and 
NF-κB at the mesenteric arterial wall.
At present, the mechanisms of increased oxidative stress 
in diabetes are demonstrated on a multifactor basis.6–9 The 
pathway of DAG-PKC is well documented as one   mechanism 
of increasing oxidative stress since such activation leads 
to altered NADPH (nicotinamide adenine dinucleotide 
  phosphate) oxidase. From our previous report, it is shown 
that curcumin can decrease superoxide at the mesenteric 
vascular wall as demonstrated by the oxygen radical-sensitive 
fluorescent probe, hydroethidine.28 It was shown that supple-
mentation with a high dose of curcumin could decrease 
malondialdehyde, the common indicator of oxidative stress, 
by almost 50% in the STZ-rat model.29,30
The interaction between NO and O2•− occurred at an 
extremely rapid rate, three times faster than the reaction rate 
between O2•− and SOD.31 Therefore, this hyperglycemia-
induced O2•− may quench NO and directly contribute to the 
dysfunction of several consequently endothelium-dependent 
processes. In addition, it is well known that diabetes-induced 
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Figure 1 Co-immunofluorescent staining of protein kinase C (PKC)-βii and vascular smooth muscle cells in mesenteric arteries (diameter = 100–120 µm) taken from 
control, diabetes mellitus (DM), and DM curcumin 300 (DM-CUR 300) groups. Double-immunofluorescent staining was performed to demonstrate PKC-βii in the mesenteric 
arteries (red fluorescence; A), α-smooth muscle actin (green fluorescence; B), and merged image (yellow; C). Magnification: ×400.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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ROS play a key role in enhancing inflammation through the 
activation of stress kinases and redox sensitive transcription 
factors such as NF-κB. NF-κB, a redox-sensitive factor and a 
key regulator of antioxidant enzymes, can initiate transcrip-
tion of many genes involved in inflammatory and immune 
response. In unstimulated cells, NF-κB is a heterodimeric 
complex that is sequestered in the cytoplasm by   interacting 
with the inhibitory I-κB family. When these cells are stimu-
lated, I-κB is phosphorylated with subsequent release of 
NF-κB resulting in the translocation of NF-κB from the 
cytoplasm to the nucleus where it can initiate the expression 
of various target genes.31,32
In this study, the results showed that the expression 
of NF-kB p65 in the small mesenteric arterial wall was 
increased significantly in the DM group. The results of 
quantitative comparison using image analysis (Global 
Lab II software) indicated that only the high doses of 
curcumin supplementation (300 mg/kg bodyweight) could 
decrease this upregulated NF-κB p65 expression significantly 
(P , 0.05) (Figure 3B).
It was reported that NF-κB was suppressed by curcumin 
through inhibiting the activity of I-κB kinase (IKK).33 
  Oxidative stress activates NF-κB-mediated transcription 
of proinflammatory mediators either through the activa-
tion of its activating inhibitor, IKK, or the enhanced 
recruitment or activation of transcriptional co-activators. In 
cancer-related inflammation, although numerous different 
pathways are activated during the inflammatory response, 
NF-κB is thought to be of the most importance.34
Activation of peroxisome proliferator-activated   receptors 
gamma (PPARγ) by curcumin resulted in inhibition of NF-κB 
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Figure 2 A) immunostaining for cyclo-oxygenase (cOX)-2 in small mesenteric 
arteries.  Sections  of  arterial  segment  show  the  endothelial  cell  layer  inwards. 
Positive immunoreactions are observed as a brown precipitate.
Notes:  cOn-nSS  (left  upper  panel),  DM-nSS  (right  upper  panel),  DM-cUR30 
(left lower panel), and DM-CUR300 (right lower panel) rats. Magnification: ×400. 
B)  expression  of  cOX-2  in  the  endothelium  layer  in  small  mesenteric  arteries 
using  image  analysis  (global  Lab  image/2  software)  measurements  in  the  DM-
nSS, DM-cUR30, and DM-cUR300 groups. Data are expressed as mean ± SeM. 
***P , 0.001 significant difference compared with control arteries; †P , 0.05 significant 
difference compared with diabetic arteries; ††P , 0.01 significant difference compared 
with diabetic arteries.
Abbreviations:  cOn-nSS,  control  with  0.9%  normal  saline;  DM-cUR30, 
diabetes-treated  with  curcumin  30  mg/kg;  DM-cUR300,  diabetes-treated  with 
curcumin 300 mg/kg; DM-nSS, diabetes treated with 0.9% normal saline; SeM, 
standard error of the mean.
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Figure  3  A)  The  expression  of  nuclear  factor-κB  p65  (nF-κB  p65)  in  small 
mesenteric  arteries  in  the  control  (left  upper  panel),  DM  (right  upper  panel), 
DM-cUR30 (left lower panel) and DM-cUR300 (right lower panel) rats. Positive 
immunoreactions  are  observed  as  a  brown  precipitate.  Magnification:  ×400. 
B)  expression  of  nF-κB  in  the  endothelium  layer  in  small  mesenteric  arteries 
using image analysis (global Lab image/2 software) measurement in the DM-nSS, 
DM-cUR30, and DM-cUR300 groups.
Notes: Data are expressed as mean ± SEM. NS, no significant difference compared 
with  diabetic  arteries.  **P  ,  0.01  significant  difference  compared  with  control 
arteries. †P , 0.05 significant difference compared with diabetic arteries. 
Abbreviations:  DM-cUR30,  diabetes-treated  with  curcumin  30  mg/kg; 
DM-cUR300,  diabetes-treated  with  curcumin  300  mg/kg;  DM-nSS,  diabetes 
treated with 0.9% normal saline; nF-κB, nuclear factor-κB; SeM, standard error 
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trans-activating activity and increased expression of PPARγ 
at both the transcriptional and translational levels in activated 
hepatic stellate cells.35 In principle, curcumin has been widely 
demonstrated to have potent antioxidant activities. It was 
reported that curcumin could increase antioxidant glutathi-
one levels by induction of glutamate cysteine ligase and act 
as an anti-inflammatory agent through inhibition of NF-κB 
signaling.36
This is the first report showing that curcumin, a polyphe-
nol, has beneficial effects on significantly decreased COX-2 
expression in the diabetic endothelial layer. Although in 
diabetes, the changes in vascular prostanoid production are 
clearly indicated in particular in association with diabetic vas-
culopathy, the role of COX-2 in diabetes is not very clear.37,38 
an in vivo relevance to diabetic complications was suggested 
by the observation of high levels of COX-2 mRNA presented 
in monocytes from type 1 or type 2 diabetic patients, but 
not from normal volunteers.39 Moreover, it has been shown 
that this high glucose-induced COX-2 mRNA expression 
was implicated by the involvement of multiple pathways, 
including the p38 MAPK, PKC, and NF-κΒ. As shown in the 
present findings, high glucose enhanced the increase of PKC, 
COX-2, and NF-κΒ,   particularly at the endothelial lining of 
mesenteric arteries. Moreover, the results of quantitative com-
parison using image analysis (Global Lab II software) showed 
that the high doses of curcumin supplementation could sig-
nificantly decrease COX-2 (P , 0.05) (Figure 2B).
In our study, the unstimulated (basal) level of 6-keto-
PGF1α (stable metabolite of PGI2) in the diabetic rats was 
markedly reduced compared with those of the control rats. 
While curcumin enhances 6-keto-PGF1α production up to 
almost basal level of control rats (Table 2), the basal levels 
of TXB2 (stable metabolite of TXA2) in diabetic rats were 
significantly elevated as compared with those of the control 
rats. These findings may have implications for the existing 
role of diabetes-induced COX-2 expression, since the prosta-
glandin which may be responsiblefor an enhanced production 
of TXA2 while reducing the production of PGI2. In addition, 
we also found a marked COX-2 immunostaining in the mes-
enteric arteries of diabetic animals, which was localized in 
the endothelial layer of the arterial wall (Figure 2A). These 
results are in accordance with other studies obtained from 
both diabetic animal models40 and human diabetes.41
Interestingly, supplementation with curcumin could 
improve the ratio of prostanoid change to higher PGI2 
than TXA2 level (Table 2). According to prostanoid levels, 
slight immunostaining for COX-2 was detected in the arter-
ies of diabetic rats supplemented with curcumin (Figure 2A). 
Thus, curcumin has been found to be effective in   inhibiting 
TXA2 synthesis in inflammation by modulating the 
  COX-2-pathway.
In conclusion, our findings provide in vivo evidence 
that curcumin supplementation (300 mg/kg) significantly 
improved diabetes-induced endothelial dysfunction related 
to its potential for COX-2 and NF-κB suppression and PKC 
inhibition, and resulted in an improved ratio of prostanoid 
products (as summarized in Figure 4).
Indeed, it is important to note that ruboxistaurin 
(LY333531) mesylate, a PKC-isozyme-selective inhibitor, is 
in Phase III clinical trials in patients with type 1 and type 2 
DM to determine its efficacy in preventing the development of 
diabetic microvascular complications.42 In addition, clinical 
  trials using up to 8000 mg curcumin per day for 3 months have 
shown no toxicity.43 Therefore, it is possible that curcumin 
supplementation might be beneficial for diabetic patients 
Table 2 Means ± SeM of basal levels of 6-keto-PgF1α and TXB2 
together with the 6-keto-PgF1α/TXB2 ratios in the mesenteric 
arteriolar bed of cOn-nSS, DM-nSS, and DM-cUR300 groups
Group 6-keto-PGF1α 
level (pg/mL)
TXB2 level 
(pg/mL)
6-keto-PGF1α/TXB2 
ratio
cOn-nSS 536.9 ± 53.3 29.4 ± 4.3 18.4 ± 0.6
DM-nSS 407.6 ± 37.1a 58.4 ± 5.8a   7.0 ± 0.06a
DM-cUR300 502.3 ± 27.6b 47.4 ± 7.2b 10.7 ± 1.0b 
Note:  aP  ,  0.05  significant  difference  compared  with  control  arterioles; 
bNo significant difference compared with control arterioles. Values are means ± SeM 
(n = 10 for each group).
Abbreviations:  cOn-nSS,  control  with  0.9%  normal  saline;  DM-cUR300, 
diabetes treated with curcumin 300 mg/kg; DM-nSS, diabetes treated with 0.9% 
normal saline; PgF1α, prostaglandin F1α; SeM, standard error of the mean; TXB2, 
thromboxane B2.
NO bioavailability
Vascular factors
Hyperglycemia
Vasoconstriction
NF-κB
COX-2 PGI2 < TXA2
DAG de novo synthesis >> PKC activation
The beneficial effects of curcumin on diabetic vascular functions
Production of ROS
Vascular inflammation
Figure 4 The beneficial effects of curcumin on diabetic vascular functions. Curcumin 
supplementation  (300  mg/kg  bodyweight)  improved  diabetes-induced  vascular 
dysfunction associated with its potential to reduce blood sugar, cOX-2 and nF-κB 
suppression, PKc inhibition, and improve the ratio of prostanoid products Pgi2 
and TXA2.
Abbreviations:  cOX-2,  cyclooxygenase-2;  DAg,  diacylglycerol;  nF-κB,  nuclear 
factor-κB; Pgi2, prostaglandin i2; PKc, protein kinase c; ROS, reactive oxygen species; 
TXA2, thromboxane A2.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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by improving microvascular functions and preventing the 
consequences of cardiovascular complications. Therefore, 
curcumin might be considered as a phytoceutical agent to 
be used for the treatment of diabetic vascular complications 
in diabetes patients in the future.
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